Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the ...
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...
Healthcare Investors lagged its benchmark as biotech faced regulatory hurdles and market rotation. Read the full analysis for ...
According to the note, the broker has retained its speculative buy rating and 25 cents price target on the ASX biotech stock.
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs ...
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an ...
The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E.
Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...
Some proposed clinical trial rules could create hurdles for smaller countries while failing to ensure high quality and ...
8don MSNOpinion
Alpha buying: Insider conviction in high-risk biotech
Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results